Richard Aplenc, MD, PhD, MSCE
Dr. Richard Aplenc is a core faculty member of the Center for Pediatric Clinical Effectiveness (CPCE) and a professor of pediatrics in the Department of Pediatrics at the Children's Hospital of Philadelphia. Dr. Aplenc’s research focuses on improving the outcomes of children with cancer, particularly acute myeloid leukemia (AML). His work involves the treatment of AML in children and the use of genetic data to predict treatment response to therapeutic interventions.
Dr. Aplenc has NIH funded research efforts in pediatric AML focused on determining the genetic predictors of treatment response (specifically relapse and infection risk) and using administrative/billing data to augment NCI funded cooperative oncology group clinical trials. He is currently leading a genome-wide genotyping effort to discover genetic variations that change the risks of relapse, life-threatening infections, and heart complications in children treated for AML. He also leads several efforts to use administrative data sets to improve the care of children with AML, particularly focusing on antibiotic and intensive care use.
Dr. Aplenc leads a large, Phase III trial for children with acute myeloid leukemia in the Children’s Oncology Group (COG) and serves as the Vice-Chair of the COG AML Committee. In addition to this work, Dr. Aplenc also leads Phase I trials for children whose cancers have not responded to standard therapy. These trials include gemtuzumab, dasatinib and obatoclax. He is the Primary Investigator at The Children’s Hospital of Philadelphia for multiple Phase I trials that are offered through the Children’s Oncology Group and he helps lead the Hematologic Malignancies Program and Experimental Therapeutics Program at CHOP.
Contact Dr. Aplenc at email@example.com.